Osteotriol may have adverse reactions such as elevated blood calcium and elevated creatinine during the medication, so taking osteotriol needs to monitor creatinine changes to avoid hypercalcemia. Osteotriol can promote intestinal absorption of calcium and regulate bone mineralization, mainly used in the treatment of postmenopausal osteoporosis, chronic renal failure, hypoparathyroidism and other diseases, should be standardized under the guidance of a doctor. Adverse reactions such as hypercalcemia, dizziness, muscle weakness, thirst, polyuria, urinary tract infection, and elevated creatinine may occur during the administration of the drug, and changes in blood creatinine should be monitored during the administration of the drug. Once the blood calcium concentration is 1mg/100ml higher than normal, or the blood creatinine is elevated to greater than 120μmol/L, the product should be stopped immediately until the blood calcium is normalized. Osteotriol is contraindicated in diseases associated with hypercalcemia, and should be contraindicated in people who are allergic to the components of this drug, which should be taken under the supervision of a medical professional.